Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219280 | 0.91 | EGLN1 (0.54) | EGLN1EGLN2 | |
| SCHEMBL1219305 | 0.89 | EGLN1 (0.49) | EGLN1EGLN2 | |
| SCHEMBL1219304 | 0.89 | EGLN1 (0.49) | EGLN1EGLN2 | |
| SCHEMBL1218406 | 0.86 | EGLN1 (0.64) | EGLN1 | |
| SCHEMBL1216454 | 0.85 | EGLN1 (0.60) | EGLN1EGLN2 | |
| SCHEMBL1218176 | 0.85 | EGLN1 (0.52) | EGLN1EGLN2 | |
| SCHEMBL1219174 | 0.84 | EGLN1 (0.57) | EGLN1 | |
| SCHEMBL2886368 | 0.83 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL2887281 | 0.80 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL2885881 | 0.80 | EGLN1 (0.47) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | EGLN1 1148/4885EGLN2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.